Thromboelastography in the Management of Coagulopathy Associated with Ebola Virus Disease

Clinical Infectious Diseases

Volumn 62, Issue 5, 2016, Pages 610-612

  Wilson, Andrew J ^a   Martin, Daniel S ^b   Maddox, Victoria ^a   Rattenbury, Simon ^a   Bland, Davis ^c   Bhagani, Sanjay ^a   Cropley, Ian ^a   Hopkins, Susan ^a   Mepham, Stephen ^a   Rodger, Alison ^b   Warren, Simon ^a   Chowdary, Pratima ^a   Jacobs, Michael ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HAEMONETICS CORPORATION   (United States)

Author keywords

Clotting; Coagulopathy; Ebola; Thromboelastography

Indexed keywords

ACETYLSALICYLIC ACID; D DIMER; ENOXAPARIN; FAVIPIRAVIR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MIL 77; MONOCLONAL ANTIBODY ZMAB; TINZAPARIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; EBOLA HEMORRHAGIC FEVER; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; PRIORITY JOURNAL; THROMBOCYTOSIS; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VIRUS LOAD; BLOOD COAGULATION DISORDERS; COMPLICATION; EVALUATION STUDY;

ADULT; BLOOD COAGULATION DISORDERS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; THROMBELASTOGRAPHY;

EID: 84960129112     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ977     Document Type: Article

References (12)

1. World Health Organization. Ebola Situation Report-11 November 2015. Available at: http://apps.who.int/ebola/current-situation/ebola-situation-report-11-november-2015. Accessed 16 November 2015.
2. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease inWest Africa-clinical manifestations and management. New Engl J Med 2014; 371:2054-7.
3. Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015; 372:40-7.
4. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371:2092-100.
5. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J Infect Dis 1999; 179:S48-53.
6. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196:S364-71.
7. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis, 2014; 210:558-66.
8. Ebihara H, Rockx B, Marzi A, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 2011; 204:S991-9.
9. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29.
10. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8.
11. Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 2005; 94:254-61.
12. Trombley AR,Wachter L, Garrison J, et al. Comprehensive panel of real-time Taq-Man polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and NewWorld hantaviruses. Am J Trop Med Hyg 2010; 82:954-60.